In this issue of JAMA Internal Medicine, Hwang et al1 assess the costs to beneficiaries of implementing a draft proposal by the Department of Health and Human Services (HHS)2 to reduce Medicare Part B costs. The plan would move certain expensive administered drugs from coverage under Medicare Part B to coverage under Medicare Part D. Medicare Part B covers drugs that are administered by infusion or injection in physician offices or hospital outpatient departments; Part D covers outpatient prescription drugs.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Crosson FJ, Christianson JB. Managing the Cost of Medicare Part B Drugs: Implications for the Program and Beneficiaries. JAMA Intern Med. 2019;179(3):380–382. doi:10.1001/jamainternmed.2018.6146
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: